| Gene symbol | KLRK1 | Synonyms | CD314, D12S2489E, KLR, NKG2-D, NKG2D | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | killer cell lectin like receptor K1 | ||||
| GTO ID | GTC2198 |
| Trial ID | NCT04107142 |
| Disease | Sarcoma | Triple-Receptor Negative Breast Cancer | Colorectal Cancer | Nasopharyngeal Disease | Prostate Cancer | Stomach Cancer |
| Altered gene | NKG2D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CTM-N2D |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour |
| Year | 2019 |
| Country | Singapore |
| Company sponsor | CytoMed Therapeutics Pte Ltd |
| Other ID(s) | CTM-N2D |
| Cohort 1 | |||||||||||
|
|||||||||||